PhaseRx Reports Third Quarter 2016 Financial Results And Provides Corporate Update

Published: Nov 08, 2016

SEATTLE, Nov. 7, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today reported financial results for the quarter and nine months ended September 30, 2016, and provided an update on its corporate activities.

"During the third quarter, we were very proud to add Peggy Phillips to our board of directors and Gordon Brandt, M.D., as our chief medical officer," said Robert W. Overell, Ph.D., president and chief executive officer. "They both bring years of experience in clinical development and drug approvals, and will expand our capabilities as our company continues to progress into clinical and ultimately commercial development."

Back to news